Omarigliptin · Marizev

Small molecule

Also known as MK-3102

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 diabetes in adults, once-weekly 25 mg and 12.5 mg tablets (Marizev); Japan was the... (JP)

This approval is outside the US-scoped market view; US development of the covered program was discontinued (see the status note below). Regulatory approval supersedes design-level evidence grading for the approved use.

Also approved (1)
JP
  • Type 2 diabetes in adults, once-weekly 25 mg and 12.5 mg tablets (Marizev); Japan was the first country to approve it
Product first approved 2015biospace.com

Development in Type 2 Diabetes stopped (2016-04) as a strategic decision by the sponsor. Source

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (11)
Other / comorbidity
NCT01703208 · Merck Sharp & Dohme LLC
2012-10-05 – 2017-03-22 · Type 2 Diabetes Mellitus
What this study did
NCT01717313 · Merck Sharp & Dohme LLC
2012-12-05 – 2015-06-19 · Type 2 Diabetes Mellitus
What this study did
NCT01697592 · Merck Sharp & Dohme LLC
2012-10-24 – 2014-05-08 · Type 2 Diabetes Mellitus
What this study did
NCT01703221 · Merck Sharp & Dohme LLC
2012-10-24 – 2014-04-25 · Type 2 Diabetes Mellitus
What this study did
Phase 2 (1)
Other / comorbidity
NCT01217073 · Merck Sharp & Dohme LLC
2010-10-08 – 2013-04-01 · Type 2 Diabetes Mellitus
What this study did
Phase 1 (3)
Other / comorbidity
NCT01767688 · Merck Sharp & Dohme LLC
2013-01-16 – 2013-03-07 · Diabetes Mellitus, Type 2
What this study did
NCT01407276 · Merck Sharp & Dohme LLC
2011-08-08 – 2012-03-23 · Chronic Renal Insufficiency, Type 2 Diabetes Mellitus
What this study did
NCT01088711 · Merck Sharp & Dohme LLC
2010-03-11 – 2010-05-11 · Type 2 Diabetes (T2D)
What this study did
Phase 4 (2)
Other / comorbidity
NCT06449235 · Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
2024-09 – 2025-06 · Type2diabetes
What this study did
NCT02906709 · Merck Sharp & Dohme LLC
2016-10-17 – 2018-08-21 · Type 2 Diabetes Mellitus
What this study did
Early phase / not applicable (2)
Other / comorbidity
NCT04365907 · British University In Egypt
2020-03-11 – 2020-05-28 · Healthy Volunteers
What this study did
NCT03362398 · British University In Egypt
2017-11-20 – 2017-11-28 · Diabetes Mellitus, Type 2
What this study did

Competitive landscape

This mechanism is crowded: 16 other tracked programmes target it, 4 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Omarigliptin (Marizev): this drugPhase 3Small moleculeDPP-4not yet graded
NCT01755156: Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Phase A) (Baseline and Week 24): Omarigliptin (Phase A) -0.54 Percent (95% CI -0.69 to -0.4) vs Placebo to Omarigliptin (Phase A) 0 Percent (95% CI -0.14 to 0.15)
NCT01698775: Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Baseline and Week 24): Omarigliptin (Phase A) -0.77 Percent (95% CI -1 to -0.54) vs Placebo to Omarigliptin (Phase A) -0.44 Percent (95% CI -0.67 to -0.21)
Alogliptin (Nesina)
Approved(overall)
Small moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Linagliptin (Tradjenta)
Approved(overall)
Small moleculeDPP-4Reliable signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued (overall)
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Sitagliptin (Januvia)
Approved(overall)
Small moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Anagliptin (Suiny)
Phase 3(overall)
Small moleculeDPP-4Reliable signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
Cofrogliptin
Phase 3(overall)
Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Evogliptin (Suganon)
Phase 3(overall)
Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Gemigliptin (Zemiglo)
Phase 3(overall)
Small moleculeDPP-4Reliable signal
NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%.
NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001
Gosogliptin
Phase 3(overall)
Small moleculeDPP-4Partial signal
NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53).
Prusogliptin (Shanzeping)
Phase 3(overall)
Small moleculeDPP-4Reliable signal
NCT04161430: HbA1c change from baseline at week 24: -0.63% (DBPR108) vs -0.02% (placebo); treatment difference -0.61 percentage points (95% CI -0.77% to -0.44%). DBPR108 was superior to placebo.
NCT04218734: Change in HbA1c at week 24: −0.70% (DBPR108 + metformin) vs −0.07% (placebo + metformin); upper limit of the 95% CI for the between-group difference was −0.39, below the 0% superiority margin (P < .001).
Retagliptin
Phase 3(overall)
Small moleculeDPP-4Partial signalNo reviewed efficacy summary
Teneligliptin (Tenelia)
Phase 3(overall)
Small moleculeDPP-4Reliable signal
NCT01805830: Change in HbA1c from baseline to week 16, teneligliptin (MP-513) vs placebo (both plus metformin): between-group difference -0.78 percentage points; fasting plasma glucose difference -1.24 mmol/L (22.42 mg/dL).
NCT01798238: Change in HbA1c at week 24, teneligliptin 20mg vs placebo: difference -0.94% (LS mean 95% CI -1.22, -0.65), p<0.001; fasting plasma glucose difference -1.21 mmol/L (95% CI -1.72, -0.70), p<0.001.
Trelagliptin (Zafatek)
Phase 3(overall)
Small moleculeDPP-4Partial signal
NCT02512068: Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)): Trelagliptin 25 mg -0.71 Percent HbA1c (Standard Error 0.087) vs Placebo and Trelagliptin 25 mg 0.01 Percent HbA1c (Standard Error 0.089)
NCT02324569: Change in HbA1c From Baseline at the End of Treatment Period I (End of Treatment Period I - End of the Screening Period) (End of the screening period (Week 0) and End of Treatment Period I (Up to Week 12)): Treatment Group I -0.56% ± 0.070 vs Treatment Group II 0.07% ± 0.067; p=<0.0001 (Treatment Group I vs Treatment Group II)
Vildagliptin (Galvus)
Phase 3(overall)
Small moleculeDPP-4Partial signal
NCT00099866: At the study end, significant HbA(1c) reductions from baseline were seen with both vildagliptin (-1.0 +/- 0.1%, P < 0.001) and metformin (-1.4 +/- 0.1%, P < 0.001) missed
Yogliptin
Phase 3(overall)
Small moleculeDPP-4Partial signalNo reviewed efficacy summary
Retagliptin / Metformin (Ruilintang)
Phase 1(overall)
Small moleculeDPP-4, AMPKPartial signalNo reviewed efficacy summary

Upcoming events

No upcoming readouts on record for this asset.